<DOC>
	<DOC>NCT00332774</DOC>
	<brief_summary>The purpose of this study is to determine the safety of Nevanac 0.1% compared to Acular LS 0.4% and Vehicle in patients treated before cataract surgery and for approximately 90 days following surgery.</brief_summary>
	<brief_title>Nevanac 3-Month Safety Study With QID Dosing</brief_title>
	<detailed_description />
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Nepafenac</mesh_term>
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Patients of any race or sex ages 10 years or older undergoing cataract extraction with planned implantation of a posterior chamber intraocular lens. Other protocoldefined inclusion criteria may apply. Under 10 Other protocoldefined exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>